Related Experiment Video
Updated: Apr 29, 2026
09:15
In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
1.3K
Risk Reduction by Direct Thrombin Antagonism During ECMO Therapy
Susanne Rohrbach1, Maurice Himmel2, Melanie Spaenig2
1Institute of Physiology, Justus-Liebig-Universitat Giessen, Giessen, Hessen, Germany.
The Thoracic and Cardiovascular Surgeon
|April 27, 2026
Summary
Direct thrombin antagonism (DTA) is a safe and effective alternative to heparin for patients on extracorporeal membrane oxygenation (ECMO). DTA demonstrated non-inferiority and superiority in reducing complications and bleeding events.
Area of Science:
- Cardiology
- Intensive Care Medicine
- Pharmacology
Background:
- Heparin-induced thrombocytopenia Type II (HITII) is a risk for ECMO patients.
- Direct thrombin antagonism (DTA) lacks approval but is being investigated as an alternative.
- This study assesses DTA's feasibility, safety, and efficacy compared to heparin.
Purpose of the Study:
- To evaluate if direct thrombin antagonism (DTA) is a feasible, safe, and non-inferior alternative to heparin in ECMO patients.
- To compare DTA with heparin regarding anticoagulation stability, bleeding, thrombosis, and survival rates.
- To determine DTA's superiority in reducing overall complications and specific adverse events.
Main Methods:
- A prospective, multicenter study analyzed 254 patients (vv- or va-ECMO) across four university hospital ICUs.
- Patients received either heparin, DTA, or switched from heparin to DTA due to suspected HITII.
- Outcomes including ICU morbidity, survival, anticoagulation stability, bleeding, and thrombosis were analyzed.
Main Results:
- No significant difference in thrombosis or system occlusions between heparin and DTA.
- DTA showed non-inferiority in weaning rates from extracorporeal support and survival.
- DTA demonstrated superiority in overall complication rates (including bleeding, stroke, amputation, thrombosis) and bleeding events alone.
Conclusions:
- Direct thrombin antagonism (DTA) is non-inferior to heparin in extracorporeal life support/ECMO therapy.
- DTA is superior to heparin in reducing overall complications, stroke, thromboembolism, and amputation.
- DTA presents a promising alternative anticoagulation strategy for ECMO patients.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
746
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
746
01:30Venous Thrombosis IV: Nursing Management
415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K